Investor sentiment has fundamentally changed. During the COVID era, investors funded good ideas. Now, they want to de-risk their investments as much as possible, often requiring solid Phase 1 and even compelling Phase 2 data before committing significant capital.

Kurma Partners' recent fundraise highlights a key challenge: while specialist and corporate investors eagerly back early-stage biotech, generalist institutional LPs are shifting away. These generalists now demand shorter hold times and favor funds investing in clinical-stage companies closer to an exit, creating a potential funding squeeze for preclinical innovation.

The abrupt failure of Arena Bioworks, a well-funded institute designed to spin off biotechs, highlights the current market's preference for de-risked clinical assets. Investors are shying away from long-timeline, platform-based models that require significant capital before generating clinical data, even those with elite scientific backing.

The focus in advanced therapies has shifted dramatically. While earlier years were about proving clinical and technological efficacy, the current risk-averse funding climate has forced the sector to prioritize commercial viability, scalability, and the industrialization of manufacturing processes to ensure long-term sustainability.

In a tight funding environment, a significant portion of startups now secure pharma partnerships *before* their Series A. This pre-validation has become a major draw for VCs, signaling a shift where corporate buy-in is needed to de-risk early-stage science for investors.

A significant disconnect exists in biotech funding. Public markets show strong recovery with over $7B in follow-on financing this quarter, while private venture financing has dropped to its lowest point since 2017. This suggests a lag effect, where public investor confidence is returning faster than private capital deployment.

As large pharmaceutical companies shift focus to acquiring clinically validated assets, a gap has emerged in early-stage development. Smaller and mid-sized pharmas, unable to compete on price for late-stage assets, are now incentivized to take on more risk and partner earlier, driving innovation.

Venture capital for US seed and Series A cell and gene therapy companies has collapsed from a historical high of 17-21% of deals to only 7% this year. The sharp decline is driven by a confluence of factors including patient deaths, persistent manufacturing challenges, and growing regulatory uncertainty.

Beyond market cycles, the real danger of scarce capital is that it cuts funding for fundamental, non-narrative-driven science at the university level. This research, often supported by government grants, is the engine of the entire biopharmaceutical ecosystem, and its decline poses a long-term threat to innovation.